News and Events

Recent News

19 November 2018

QurAlis Raises $5.5 million Seed Round
-- Wins Pfizer Sponsored Golden Ticket to LabCentral --
-- Becomes Resident of JLABS @ LabCentral --
Download PDF

13 November 2018

Ribometrix Announces $30 Million Series A Funding to Advance Pipeline of RNA-Targeting Small Molecule Therapies.
Download PDF

30 May 2018

F‐star Announces Early Exercise by Denali Therapeutics of
its Option to Acquire F‐star Gamma.
Download PDF

5 April 2018

QurAlis Launches with Seed Funding from MPH, Amgen and Alexandria, United in the Fight to Cure ALS.
Download PDF

15 December 2017

QurAlis has won the Amgen Golden Ticket at LabCentral.
Download PDF

31 October 2017

Ribometrix Raises $7.5M In Seed Funding to Advance Platform for Discovering and Developing Small Molecule Modulators of RNA to Treat Human Diseases.
Download PDF

6 September 2017

Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer,
Advancing Leadership in Immuno-Oncology. Download PDF

4 June 2017

F-star Expands its Relationship with Merck through a new Strategic Collaboration to Develop Bispecific Antibodies in Immuno-Oncology. Download PDF

3 May 2017

Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist
RGT100 and Appoints Eugen Leo as Chief Medical Officer. Download PDF

25 April 2017

Forge Therapeutics Raises $15M Series A Financing to Develop First Novel Gram-Negative Antibiotic In Decades. Download PDF

13 February 2017

miRagen Therapeutics Completes Merger with Signal Genetics and Concurrent $40.7 Million Equity Financing. Download PDF

3 November 2016

miRagen Therapeutics Announces Presentation of MRG-106 Clinical Data at American Society of Hematology Annual Meeting. Download PDF

31 October 2016

miRagen Therapeutics and Signal Genetics Sign Merger Agreement. .Download PDF

9 September 2016

miRagen Therapeutics Appoints Kevin Koch, Ph.D., to Its Board of Directors .Download PDF

25 August 2016

F‐star Announces Collaborative Agreement with Denali Therapeutics for the  Development of a Multispecific Antibody Platform to Deliver Therapeutics  Across the Blood‐Brain Barrier.Download PDF

2 March 2016

miRagen Therapeutics Initiates First Clinical Trial for MRG-106 in Lymphoma Patients.Download PDF

29 February 2016

Thrasos Announces Promising Results for Phase 2 THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury(AKI).Download PDF

11 January 2016

F-star Enters into Collaborative Discovery & Development Agreement with AbbVie for Bispecific Antibodies in Immuno-oncology.Download PDF

10 November 2015

miRagen Therapeutics Secures $41 million Series C Financing to Advance Two MicroRNA Programs into Clinical Trials.Download PDF

7 July 2015

Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Studay for Acute Kidney Injury.Download PDF

31 March 2015

Thrasos Secures $21 Million to Complete Phase 2 Study of THR-184 in the Prevention of Acute Kidney Injury and Expand the Company's Renal Portfolio.Download PDF

4 November 2014

F-star Announces the Formation of Second Asset-Centric Vehicle, F-star Beta Ltd. Download PDF

28 October 2014

Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy. Download PDF

16 September 2014

Thrasos Announces Successful Formal Interim Analysis and Clinical Update.Download PDF

25 August 2014

Janssen Affiliate Cilag GmbH International Acquires Covagen AG.Download PDF

23 June 2014

Genocea Announces Positive Top-Line Phase 1 Results for Novel Universal Pneumococcus
Vaccine Candidate GEN-004.Download PDF

9 January 2014

F-star achieves milestone in collaboration with Boehringer Ingelheim.Download PDF

23 December 2013

Genocea Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering. Download PDF

6 December 2013

Covagen and Tanabe Research Laboratories Expand Strategic Research Collaboration for Development of Bispecific FynomAbs.Link

5 December 2013

Genocea Biosciences Initiates Phase 1 Study of Vaccine Candidate Gen-004 to Prevent Infections Caused by Pneumococcus. Download PDF

23 October 2013

F-star announces formation of new asset-centric vehicle, F-star Alpha Ltd, with €9.4m Series A investment.Download PDF

6 June 2013

Pronota Is To Receive Patent On Biomarker For Diagnosing Renal Failure In The US Despite Prometheus.Download PDF

5 November 2012

International Consortium Awarded 6 Million Euro To Validate Pre-Eclampsia Early Detection Tests.Download PDF

2 November 2012

Genkyotex's NOX Inhibitor GKT137831 Phase I Data Presented at Kidney Week 2012.Download PDF

25 October 2012

Thrasos Secures $35 Million to Fund THR-184 Phase 2 Clinical Program for Treatment of Acute Kidney Injury.Download PDF

17 October 2012

Covagen enters into a strategic research collaboration and
license agreement with Mitsubishi Tanabe for the development of
bispecific FynomAbs.Download PDF

10 October 2012

Genocea Closes $30 Million in Series C Financing. The Bill & Melinda Gates Foundation and CVF join as new investors.Download PDF

15 August 2012

Genocea Initiates a Phase 1/2a Study with its Therapeutic Vaccine Candidate for Herpes Simplex Virus-2 (HSV-2)Download PDF

9 July 2012

Pronota's Risk Stratification Test Breaks New Ground in the Early Detection of Pre-term Pre-eclampsiaDownload PDF

9 July 2012

Genkyotex Raises CHF25 Million in Series C Round ExtensionDownload PDF

22 June 2012

Genkyotex Announces Successful Phase Ia Data with First in Class NOX
Inhibitor GKT137831Download PDF

16 March 2012

Pronota Strengthens Management Team
Former VP Corporate Development Genzyme joins as CBO.Download PDF

15 March 2012

Shire to acquire FerroKin BioSciences, Inc., and its Phase
2 iron chelator treatment.Download PDF

20 January 2012

Pronota announces EUR 3.7 million Series C financing ; management and board changes.Download PDF

30 December 2011

Syndexa Pharmaceuticals Expands Series B1 Financing Round with Investment by MP Healthcare Venture Management, Inc.

31 October 2011

GenKyoTex Starts Phase 1 Trial with First in Class NOX inhibitor GKT137831. Dual NOX1/4 Inhibitor Targets Treatment of Diabetic Nephropathy Download PDF

7 September 2011

F-Star and Merck Serono to Collaborate in the Discovery and Development of Novel Targeted BiologicsDownload PDF

6 September 2011

FierceBiotech Names F-star a 2011 Fierce 15 CompanyLink

24 May 2011

GenKyoTex raises CHF 18 million in a Series C Venture Financing to develop NOX enzyme inhibitorsDownload PDF

16 May 2011

Covagen nominates Franz Hefti as new member of the Board of DirectorsDownload PDF

13 April 2011

f-star raises €15M in a New Financing led by SR OneDownload PDF

22 February 2011

Pronota and Molecuence announce collaboration in protein biomarker discoveryDownload PDF

3 January 2011

Genocea Biosciences Closes $35 Million Series B FinancingDownload PDF


29 November 2010

Covagen closes Series A financing round with Seroba Kernel as lead investorDownload PDF

22 November 2010

f-star and Boehringer Ingelheim to collaborate in discovery and development of therapeutic antibodiesDownload PDF

8 November 2010

Covagen and Roche extend collaboration on the use of Fynomers in drug discoveryDownload PDF

8 September 2010

FerroKin BioSciences Announces Start of a Phase 2 Clinical Trial of FBS0701 as a Novel Treatment for Transfusional Iron Overload Download PDF

22 June 2010

MP Healthcare Appoints Tak Mukohira as President.Download PDF

9 June 2010

Ferrokin Biosciences Completes $ 12million Financing.Download PDF

17 May 2010

Pronota Raises an Additional EUR 1.5 Million in a Final Close of its Series B Financing Totaling EUR 7.9 Million Download PDF

6 January 2010

f-Star Raises EUR 8 Million in an Extended Series A Financing Co-Led by MP Healthcare Venture Management and Merck Serono Ventures Download PDF

16 December 2009

Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company Download PDF

1 December 2009

Covagen Adds Ventech to Investor Syndicate and Further Strengthens its Scientific Advisory Board Download PDF

29 October 2009

Pronota Raises an Additional EUR 1.3 Million it its Series B Financing
Download PDF

5 October 2009

Covagen Adds New Investor to Financing Round and Advances Novel Protein Scaffold Technology in Inflammation and Oncology Download PDF

14 July 2009

Pharmeste Advances Neuropathic Pain Therapy to Phase I Clinical Trial with its Lead Compound PHE377 Download PDF

2 October 2008

Intradigm Raises $18.5 Million in Series B Financing Download PDF

29 September 2008

MP Healthcare Venture Management, Inc. Invests in Pharmeste
Download PDF

Meet us at the following events:
  • 3 October 2018

    The Deal Meeting, Belmont, MA

  • 17-19 October 2018

    Voice.Health Summit, Boston, MA

  • 20-24 October 2018

    ASEMV 2018 Annual Meeting, Baltimore, MD

  • 7-9 December 2018

    The 29th International Symposium on ALS/MND, Glasgow, UK

  • 7-9 January 2019

    Biotech Showcase, San Francisco, CA

  • 7-10 January 2019

    JP Morgan Healthcare Conference, San Francisco, CA